Hashtag

PR Newswire

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
  • Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients
  • PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation population
  • Data demonstrated elacestrant significantly reduced the risk of...

Read more: Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD...

Health & Wellness

9 Ways to Get the Most Out of Your Workout

Chloe Taylor - avatar Chloe Taylor

While some people have the tide and motivation to spend hours at the gym, most of us don’t have such a luxury. Instead, we need to do our best to maximize our workouts and get the best results i...

Best Treatment for Jaw Clenching & Teeth Grinding

NewsServices.com - avatar NewsServices.com

Jaw clenching and bruxism are frequent tendencies among persons who are under a lot of stress. Given how demanding today's world is, it's no surprise that stress is a continual factor. Several hob...

Tooth tips: 5 bits of advice for looking after your dental crown

NewsServices.com - avatar NewsServices.com

Dental crowns are caps that are installed to protect damaged teeth, strengthen weakened teeth and produce an appealing aesthetic. People often receive this treatment if their tooth/teeth are badl...

Online Purchase of Health Products – Confused

NewsServices.com - avatar NewsServices.com

If you have ever decided to purchase health products online, you may be confused by the sheer number of products. There are so many different products available out there, not all of them are grea...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion